| Valuation method | Value, € | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 389.90 | 1525 |
| Intrinsic value (DCF) | 14.27 | -41 |
| Graham-Dodd Method | n/a | |
| Graham Formula | 15.10 | -37 |
MeVis Medical Solutions AG (M3V.DE) is a Germany-based medical technology company specializing in advanced software solutions for medical imaging analysis. Founded in 1992 and headquartered in Bremen, the company develops and markets software for image-based early detection and diagnosis of critical diseases such as breast cancer, lung disorders, liver conditions, and neurological diseases. MeVis serves medical device manufacturers, IT platform providers, and clinical end-users across the U.S. and Europe. Its product portfolio includes solutions for computed tomography (CT), digital mammography, MRI, and sonography, alongside specialized services like software development, technical visualization, and online clinician training. As a subsidiary of Varex Imaging Deutschland AG, MeVis operates in the high-growth healthcare IT sector, leveraging AI and digital innovation to enhance diagnostic accuracy and efficiency. With a strong focus on teleradiology and precision medicine, the company is well-positioned in the expanding medical imaging software market.
MeVis Medical Solutions AG presents a niche investment opportunity in the medical imaging software sector, supported by stable profitability (net income of €4.56M in FY 2023) and a debt-free balance sheet. The company’s negative beta (-0.136) suggests low correlation with broader market movements, potentially offering defensive appeal. However, its small market cap (~€47M) and limited revenue scale (€16.97M) pose liquidity risks and dependence on key clients. The dividend yield (~2% based on a €0.95/share payout) adds income appeal, but growth hinges on adoption of its AI-driven diagnostic tools in competitive markets dominated by larger players. Investors should weigh its technological expertise against sector consolidation risks.
MeVis Medical Solutions competes in the specialized medical imaging software segment, differentiating through disease-specific AI algorithms (e.g., breast cancer detection) and partnerships with device manufacturers. Its subsidiary status under Varex Imaging provides backend integration advantages with imaging hardware, though this may limit standalone scalability. The company’s focus on clinician training and teleradiology addresses underserved niches, but it lacks the cloud-based platform breadth of larger rivals like Siemens Healthineers or GE Healthcare. Financially, MeVis’s profitability (27% net margin) outperforms many small-cap peers, but R&D spending is modest compared to AI-focused competitors. Its European base offers regional market access but limits U.S. penetration against local giants. Competitive threats include commoditization of imaging analytics and consolidation among OEM customers.